protolabs Archives - Medical Design Sourcing

Protolabs has ‘true silicone’ for medical devices

True silicone from Protolabs comes in a wide range of durometers (20A to 60A) that enables everything from spongy to hard parts. {Image by executive editor Chris Newmarker]

Protolabs is using MD&M Minneapolis this week to promote its new “true silicone” 3D printing offering that is gaining attention from medical device developers.

“It’s only been out for a couple of months, but it’s getting really good reception from medical customers,” said David Giebenhain, Protolabs’ global product director of 3D printing. (Check out Protolabs at Booth No. 2300 at MD&M Minneapolis — which runs today and tomorrow.)

The offering helps set Protolabs a cut above other 3D printing providers who offer materials that are “like” the real thing, but not the actual material.

The Maple Plain, Minnesota–based quick-turn manufacturing giant is offering true s…

Proto Labs stock dives on Q3 earnings miss

Proto Labs (NYSE:PRLB) stock dropped more than 18 percent after the digital manufacturing service provider reported third-quarter earnings that missed Wall Street’s expectations.

Maple Plain, Minnesota-based Proto Labs this morning reported earnings of $4.8 million (or 17¢ per share) off sales of $125.3 million. That’s a 67% decrease from Q3 2020’s earnings of $14.7 million (55¢ per share) off sales of $107.5 million.

Adjusted to exclude one-time items, earnings per share were 35¢, or 8¢ below Wall Street’s consensus forecast, where analysts were looking for adjusted EPS of 43¢ on sales of $127.3 million.

Get the full story on our sister site, Medical Design & Outsourcing.

Proto Labs stock dives on Q3 earnings miss

Proto Labs (NYSE:PRLB) stock dropped more than 18% after the digital manufacturing service provider reported third-quarter earnings that missed Wall Street’s expectations.

Maple Plain, Minnesota–based Proto Labs this morning reported earnings of $4.8 million (or 17¢ per share) off sales of $125.3 million. That’s a 67% decrease from Q3 2020’s earnings of $14.7 million (55¢ per share) off sales of $107.5 million.

Adjusted to exclude one-time items, earnings per share were 35¢, or 8¢ below Wall Street’s consensus forecast, where analysts were looking for adjusted EPS of 43¢ on sales of $127.3 million.

“We achieved record revenue in the third quarter amidst a difficult backdrop of global supply chain issues and labor and materials constraints,” Proto Labs resident and CEO Rob Bodor said in a news release. “During the quarter, we also received external recognition of our best-in-class digital manufacturing capabilities as the World Economic Forum announced ou…

Protolabs reports mixed-bag results for Q2

Protolabs (NYSE: PRLB) posted second-quarter earnings today that missed the consensus forecast on Wall Street, though the company beat on revenue.

The Maple Plain, Minn–based digital manufacturing outsourcer — which serves medtech and a host of other industries — reported profits of $12.9 million, or 47¢ per share, on sales of $123.0 million for the three months ended June 30, 2021, for a bottom-line gain of 2.4% and sales growth of 15.4% compared with Q2 2020.

Adjusted to exclude one-time items, earnings per share were 39¢, a nickel behind The Street, where analysts were looking EPS of 44¢ on sales of $122.2 million.

Get the full story on our sister site Medical Design & Outsourcing.

Protolabs reports mixed-bag results for Q2

Protolabs (NYSE: PRLB) posted second-quarter earnings today that missed the consensus forecast on Wall Street, though the company beat on revenue.

The Maple Plain, Minn–based digital manufacturing outsourcer — which serves medtech and a host of other industries — reported profits of $12.9 million, or 47¢ per share, on sales of $123.0 million for the three months ended June 30, 2021, for a bottom-line gain of 2.4% and sales growth of 15.4% compared with Q2 2020.

Adjusted to exclude one-time items, earnings per share were 39¢, a nickel behind The Street, where analysts were looking EPS of 44¢ on sales of $122.2 million.

“During the second quarter of 2021, we experienced strong demand and delivered record revenues despite the challenges of labor availability in the U.S. We are emerging from the pandemic stronger than ever in the custom parts space,” Protolabs CEO Rob Bodor said in a news release.

Added CFO John Way: “The environment is ripe for…

Protolabs meets on earnings, beats on revenue in Q1

Protolabs (NYSE: PRLB) today met the Wall Street consensus on its Q1 earnings, surpassing analysts’ expectations when it came to revenue.

The Maple Plain, Minn.–based digital manufacturer — which supports medtech and many other industries — reported profits of $3.7 million, or 13¢ per share — about a quarter of the profits that Protolabs saw in Q1 2020. Revenue of $116.1 million was up slightly from a year ago.

Adjusted to exclude one-time items, earnings per share were 40¢, meeting The Street’s expectations, where analysts were looking EPS of 40¢ on sales of $113.22 million.

“During the first quarter of 2021, we achieved two very important milestones, the successful launch of Protolabs 2.0 and the transformative acquisition of 3D Hubs, which will enable us to accelerate growth,” Protolabs CEO Rob Bodor said in a news release.

“I am very pleased that we also delivered strong first-quarter financial performance within our expectations. …

Protolabs to acquire 3D Hubs for up to $330M

Protolabs (NYSE: PRLB) today announced it plans to acquire Amsterdam-based Hubs, an online manufacturing platform that provides engineers with on-demand access to a global network of approximately 240 manufacturing partners. The transaction creates a comprehensive digital manufacturing offer for custom parts, expanding Protolabs’ breadth of capabilities as well as adding a broader offering of pricing and lead-time options, according to a news release from the Maple Plain, Minn-based company. Get the full story on our sister site, Medical Design & Outsourcing.

Protolabs stock takes a hit despite beating The Street for Q2

Shares in Protolabs (NYSE: PRLB) dropped by nearly 9% today on news of second-quarter medical device sales that would have been worse had it not been for orders that came in response to COVID-19.

The Maple Plain, Minn.-based rapid manufacturing company reported profits of $12.6 million or $0.47 per share, on sales of $106.58 million for the three months ended June 30, 2020, for a bottom-line drop of -22% on a sales shrinkage of -8.86% compared with Q2 2019.

Get the full story on our sister site, Medical Design & Outsourcing.